Gastrointestinal stromal tumor natural history: Difference between revisions
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{PSD}} | ||
{{Gastrointestinal stromal tumor}} | {{Gastrointestinal stromal tumor}} | ||
| Line 16: | Line 17: | ||
==Complications== | ==Complications== | ||
*Gastrointestinal bleeding | *[[Gastrointestinal bleeding]] | ||
*Bowel obstruction | *[[Bowel obstruction]] | ||
*Bowel perforation | *[[Bowel perforation]] | ||
*Peritonitis | *[[Peritonitis]] | ||
*Volvulus | *[[Volvulus]] | ||
*Intussusception | *[[Intussusception]] | ||
*Surgical complications associated with resection include: | *Surgical [[complications]] associated with [[resection]] include: | ||
**Atelectasis | **[[Atelectasis]] | ||
**Pneumonia | **[[Pneumonia]] | ||
**Urinary tract infection | **[[Urinary tract infection]] | ||
**Abscess formation | **[[Abscess]] formation | ||
**Small-bowel obstruction | **[[Small bowel obstruction|Small-bowel obstruction]] | ||
**Deep venous thrombosis | **[[Deep vein thrombosis|Deep venous thrombosis]] | ||
==Prognosis== | ==Prognosis== | ||
| Line 37: | Line 38: | ||
*Tumor location<ref>{{Cite web | title =Risk Assessment and Prognosis | *Tumor location<ref>{{Cite web | title =Risk Assessment and Prognosis | ||
| url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_1 }}</ref> | | url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_1 }}</ref> | ||
| Line 48: | Line 48: | ||
**Patients with mitotic rate of >10 per 50 HPF have an average survival period of 1.5-2 years | **Patients with mitotic rate of >10 per 50 HPF have an average survival period of 1.5-2 years | ||
**Patients with mitotic rate <10 per HPF have an average survival period of 8 years. | **Patients with mitotic rate <10 per HPF have an average survival period of 8 years. | ||
==Refrences== | ==Refrences== | ||
Revision as of 16:42, 15 December 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor natural history On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor natural history |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor natural history |
Overview
Most common site of involvement of GIST is stomach(70%).
Natural history
Common sites of involvement include:
- Stomach: 70%
- Small intestine: 20-25%
- Anorectum: 7%
- Oesophagus
GISTs occur not only anywhere along the gastrointestinal tract, but also in the mesentery, omentum and retroperitoneum, which is called extra-gastrointestinal GISTs. Metastatic lesions may also be seen in cases of malignant extra-gastrointestinal GISTs
Complications
- Gastrointestinal bleeding
- Bowel obstruction
- Bowel perforation
- Peritonitis
- Volvulus
- Intussusception
- Surgical complications associated with resection include:
Prognosis
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters:
- Mitotic index (mitoses per 50 high-power fields)
- Tumor size
- Tumor location[1]
- Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary.
- Prognosis of GIST depends upon size, location, spread and mitotic rate of the tumor.
- Patients with gastric GIST have been reported to have better outlook as compared to patients with extragastric GIST.
- Patients with localized primary disease have a average survival period of 5 years.
- Patients with malignant lesions and metastasis have an average survival period of 1-2 years.
- Patients with mitotic rate of >10 per 50 HPF have an average survival period of 1.5-2 years
- Patients with mitotic rate <10 per HPF have an average survival period of 8 years.